Jan 31, 2018   SOURCE: PR NewsWire

CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary

DUBLIN, Jan. 31, 2018 /PRNewswire/ --

The "MarketVIEW: CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report consists of a comprehensive executive presentation detailing the disease background, epidemiology of the disease, current therapies and treatment options, and novel immunotherapies with a focus on CAR-T. Also included is a summary and analysis of published and registered ongoing CAR-T clinical studies detailing the phases, targets under investigation, study status and summary of study protocols (patient numbers, dosing, study objectives). Key significant data available to date is discussed in further detail.

US estimates for multiple myeloma incidence in 2017 are >30,000 new cases diagnosed and approximately 12,500 deaths. The age adjusted incidence in the US is ~ 4 per 100,000 and, in the UK the value is ~9 per 100,000. The worldwide incidence of multiple myeloma was >114,000 new cases in 2012.

Despite significant improvements in treatments including the use of immunomodulatory drugs (e.g. lenalidomide, pomalidomide) and proteasome inhibitors (e.g. bortezomib, carfilzomib, ixazomib) in the first line setting, and the recent approvals for histone deacetylase inhibitors (e.g. panobinostat) and monoclonal antibodies (daratumumab and elotuzumab), most patients eventually relapse or are refractory and the management of the disease remains challenging.

Novel immunotherapeutic approaches in the treatment of multiple myeloma include checkpoint inhibitors, monoclonal antibodies, vaccines and adoptive T-cell therapies. Chimeric Antigen Receptor (CAR-T) approaches are also being investigated by several companies including Novartis, Kite/Gilead, Juno Therapeutics/Celgene, Bluebird therapeutics/Celgene, Legend Biotech/J&J as well as several companies in early stage clinical investigations (Autolus, Poseida Therapeutics, Celyad).

Companies Mentioned 

    --  Autolus Ltd
    --  Bluebird Bio
    --  Celgene
    --  Celyad
    --  Chinese PLA General Hospital
    --  Fred Hutch
    --  Gilead
    --  J&J Autolus
    --  Juno Therapeutics, Inc.
    --  Kite
    --  Legend Biotech
    --  MSKCC
    --  Nanjing Legend Biotech Co.
    --  National Cancer Institute
    --  Novartis
    --  Poseida Therapeutics
    --  U. Penn

Key Topics Covered:

1. Executive Summary

2. Multiple Myeloma - Disease Background and Risk Factors

3. Multiple Myeloma - Diagnosis, Symptoms, Staging and Prognosis

4. Multiple Myeloma - Epidemiology

5. Multiple Myeloma - Treatment and Unmet Need

6. Novel Treatments for Multiple Myeloma - Immunotherapy Approaches

7. Bibliography

For more information about this report visit https://www.researchandmarkets.com/research/zdvq68/marketview_cart?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-disease-and-pipeline-summary-300591001.html

SOURCE Research and Markets